Improvement of social functioning in patients with first-episode schizophrenia using blonanserin treatment: a prospective, multi-centre, single-arm clinical trial

This clinical trial primarily aimed to investigate the effects of blonanserin on social functioning in patients with first-episode schizophrenia. In this prospective, multi-centre, single-arm clinical trial study, blonanserin (flexible oral dose ranging from 8mg to 24mg per day) was given 26 weeks....

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in psychiatry 2024-03, Vol.15, p.1345978-1345978
Main Authors: Gao, Tianqi, Deng, Hong, Sheng, Jianhua, Wu, Bin, Liu, Zhening, Yang, Fude, Wang, Lina, Hu, Shaohua, Wang, Xijin, Li, Haiyun, Pu, Chengcheng, Yu, Xin
Format: Article
Language:English
Subjects:
blonanserin
clinical trial
first-episode schizophrenia
Psychiatry
social functioning
symtomatic and neurocognitive improvement
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c420t-16f979b16d6f74d8f529cac80ec1d3f4407bb266249980bd7b2a127e3e5cae103
container_end_page 1345978
container_issue
container_start_page 1345978
container_title Frontiers in psychiatry
container_volume 15
creator Gao, Tianqi
Deng, Hong
Sheng, Jianhua
Wu, Bin
Liu, Zhening
Yang, Fude
Wang, Lina
Hu, Shaohua
Wang, Xijin
Li, Haiyun
Pu, Chengcheng
Yu, Xin
description This clinical trial primarily aimed to investigate the effects of blonanserin on social functioning in patients with first-episode schizophrenia. In this prospective, multi-centre, single-arm clinical trial study, blonanserin (flexible oral dose ranging from 8mg to 24mg per day) was given 26 weeks. Outcome measures included the Personal and Social Performance (PSP) scale for evaluating social functioning, the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB) for measuring neurocognitive performance, and the Positive and Negative Syndrome Scale (PANSS) for assessing symptom severity. The primary endpoint was social function improvement evaluated by PSP scale at the end of blonanserin treatment. And the secondary endpoint was to validate the efficacy and neurocognitive effects of blonanserin. Adverse drug reactions (ADRs) were also recorded and analysed. A total of 96 patients with first-episode schizophrenia were recruited and proceeded to analysis. Fifty-one participants (53.1%) completed the PSP scale measurements at baseline and week 26. Following 26 weeks of blonanserin treatment, all outcome measurements demonstrated significant improvement during the follow-up period. Notably, PSP scores exhibited a continuous increase up to 68.1% ± 103.7% at the end of the treatment (46.6 ± 14.6 at baseline, 69.4 ± 17.4 at week 26, p
doi_str_mv 10.3389/fpsyt.2024.1345978
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_af6c298ac1d64696bcd29c2b80ad2944</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_af6c298ac1d64696bcd29c2b80ad2944</doaj_id><sourcerecordid>3033008070</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-16f979b16d6f74d8f529cac80ec1d3f4407bb266249980bd7b2a127e3e5cae103</originalsourceid><addsrcrecordid>eNpVksuOFCEUhitG40zGeQEXhqULq-VWFLgxZuKlk0nc6JpQFHQzoaAEqs34OD6pVHc7mWHDgXP-7xzI3zSvEdwQwsV7O-f7ssEQ0w0itBM9f9ZcIsZoCxmFzx_FF811znewLiIEYd3L5oLwrkdC0Mvm73aaUzyYyYQCogU5aqc8sEvQxcXgwg64AGZVXC3I4Lcre2BdyqU1s8txNCDrvfsT530ywSmw5FUy-BhUyCZVbUlGlRX_AShQe-XZVPTBvAPT4otrdU2lelqF3rQqTUB7F5yuY5RUh3nVvLDKZ3N93q-an18-_7j51t5-_7q9-XTbaophaRGzohcDYiOzPR257bDQSnNoNBqJpRT2w4AZw1QIDoexH7BCuDfEdFoZBMlVsz1xx6ju5JzcpNK9jMrJ40VMO6lScdobqSzTWHBVyYwywQY91mZ44FDVgNLK-nhizcswmfH4RuWfQJ9mgtvLXTxIBAXnDJFKeHsmpPhrMbnIyWVtvFfBxCVLAgmBkMN-HRyfSnX93ZyMfeiDoFzNIo9mkatZ5NksVfTm8YQPkv_WIP8Abm7BuQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3033008070</pqid></control><display><type>article</type><title>Improvement of social functioning in patients with first-episode schizophrenia using blonanserin treatment: a prospective, multi-centre, single-arm clinical trial</title><source>PubMed (Medline)</source><creator>Gao, Tianqi ; Deng, Hong ; Sheng, Jianhua ; Wu, Bin ; Liu, Zhening ; Yang, Fude ; Wang, Lina ; Hu, Shaohua ; Wang, Xijin ; Li, Haiyun ; Pu, Chengcheng ; Yu, Xin</creator><creatorcontrib>Gao, Tianqi ; Deng, Hong ; Sheng, Jianhua ; Wu, Bin ; Liu, Zhening ; Yang, Fude ; Wang, Lina ; Hu, Shaohua ; Wang, Xijin ; Li, Haiyun ; Pu, Chengcheng ; Yu, Xin</creatorcontrib><description>This clinical trial primarily aimed to investigate the effects of blonanserin on social functioning in patients with first-episode schizophrenia. In this prospective, multi-centre, single-arm clinical trial study, blonanserin (flexible oral dose ranging from 8mg to 24mg per day) was given 26 weeks. Outcome measures included the Personal and Social Performance (PSP) scale for evaluating social functioning, the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB) for measuring neurocognitive performance, and the Positive and Negative Syndrome Scale (PANSS) for assessing symptom severity. The primary endpoint was social function improvement evaluated by PSP scale at the end of blonanserin treatment. And the secondary endpoint was to validate the efficacy and neurocognitive effects of blonanserin. Adverse drug reactions (ADRs) were also recorded and analysed. A total of 96 patients with first-episode schizophrenia were recruited and proceeded to analysis. Fifty-one participants (53.1%) completed the PSP scale measurements at baseline and week 26. Following 26 weeks of blonanserin treatment, all outcome measurements demonstrated significant improvement during the follow-up period. Notably, PSP scores exhibited a continuous increase up to 68.1% ± 103.7% at the end of the treatment (46.6 ± 14.6 at baseline, 69.4 ± 17.4 at week 26, p&lt;0.001), indicating positive effects on social functioning that were already noticeable by week 8. Blonanserin treatment exhibited favourable effects on social functioning in individuals with first-episode schizophrenia. The results suggest that blonanserin was effective treatment options for patients with schizophrenia encountering functional impairments.</description><identifier>ISSN: 1664-0640</identifier><identifier>EISSN: 1664-0640</identifier><identifier>DOI: 10.3389/fpsyt.2024.1345978</identifier><identifier>PMID: 38571994</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>blonanserin ; clinical trial ; first-episode schizophrenia ; Psychiatry ; social functioning ; symtomatic and neurocognitive improvement</subject><ispartof>Frontiers in psychiatry, 2024-03, Vol.15, p.1345978-1345978</ispartof><rights>Copyright © 2024 Gao, Deng, Sheng, Wu, Liu, Yang, Wang, Hu, Wang, Li, Pu and Yu.</rights><rights>Copyright © 2024 Gao, Deng, Sheng, Wu, Liu, Yang, Wang, Hu, Wang, Li, Pu and Yu 2024 Gao, Deng, Sheng, Wu, Liu, Yang, Wang, Hu, Wang, Li, Pu and Yu</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c420t-16f979b16d6f74d8f529cac80ec1d3f4407bb266249980bd7b2a127e3e5cae103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988613/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988613/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38571994$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gao, Tianqi</creatorcontrib><creatorcontrib>Deng, Hong</creatorcontrib><creatorcontrib>Sheng, Jianhua</creatorcontrib><creatorcontrib>Wu, Bin</creatorcontrib><creatorcontrib>Liu, Zhening</creatorcontrib><creatorcontrib>Yang, Fude</creatorcontrib><creatorcontrib>Wang, Lina</creatorcontrib><creatorcontrib>Hu, Shaohua</creatorcontrib><creatorcontrib>Wang, Xijin</creatorcontrib><creatorcontrib>Li, Haiyun</creatorcontrib><creatorcontrib>Pu, Chengcheng</creatorcontrib><creatorcontrib>Yu, Xin</creatorcontrib><title>Improvement of social functioning in patients with first-episode schizophrenia using blonanserin treatment: a prospective, multi-centre, single-arm clinical trial</title><title>Frontiers in psychiatry</title><addtitle>Front Psychiatry</addtitle><description>This clinical trial primarily aimed to investigate the effects of blonanserin on social functioning in patients with first-episode schizophrenia. In this prospective, multi-centre, single-arm clinical trial study, blonanserin (flexible oral dose ranging from 8mg to 24mg per day) was given 26 weeks. Outcome measures included the Personal and Social Performance (PSP) scale for evaluating social functioning, the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB) for measuring neurocognitive performance, and the Positive and Negative Syndrome Scale (PANSS) for assessing symptom severity. The primary endpoint was social function improvement evaluated by PSP scale at the end of blonanserin treatment. And the secondary endpoint was to validate the efficacy and neurocognitive effects of blonanserin. Adverse drug reactions (ADRs) were also recorded and analysed. A total of 96 patients with first-episode schizophrenia were recruited and proceeded to analysis. Fifty-one participants (53.1%) completed the PSP scale measurements at baseline and week 26. Following 26 weeks of blonanserin treatment, all outcome measurements demonstrated significant improvement during the follow-up period. Notably, PSP scores exhibited a continuous increase up to 68.1% ± 103.7% at the end of the treatment (46.6 ± 14.6 at baseline, 69.4 ± 17.4 at week 26, p&lt;0.001), indicating positive effects on social functioning that were already noticeable by week 8. Blonanserin treatment exhibited favourable effects on social functioning in individuals with first-episode schizophrenia. The results suggest that blonanserin was effective treatment options for patients with schizophrenia encountering functional impairments.</description><subject>blonanserin</subject><subject>clinical trial</subject><subject>first-episode schizophrenia</subject><subject>Psychiatry</subject><subject>social functioning</subject><subject>symtomatic and neurocognitive improvement</subject><issn>1664-0640</issn><issn>1664-0640</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVksuOFCEUhitG40zGeQEXhqULq-VWFLgxZuKlk0nc6JpQFHQzoaAEqs34OD6pVHc7mWHDgXP-7xzI3zSvEdwQwsV7O-f7ssEQ0w0itBM9f9ZcIsZoCxmFzx_FF811znewLiIEYd3L5oLwrkdC0Mvm73aaUzyYyYQCogU5aqc8sEvQxcXgwg64AGZVXC3I4Lcre2BdyqU1s8txNCDrvfsT530ywSmw5FUy-BhUyCZVbUlGlRX_AShQe-XZVPTBvAPT4otrdU2lelqF3rQqTUB7F5yuY5RUh3nVvLDKZ3N93q-an18-_7j51t5-_7q9-XTbaophaRGzohcDYiOzPR257bDQSnNoNBqJpRT2w4AZw1QIDoexH7BCuDfEdFoZBMlVsz1xx6ju5JzcpNK9jMrJ40VMO6lScdobqSzTWHBVyYwywQY91mZ44FDVgNLK-nhizcswmfH4RuWfQJ9mgtvLXTxIBAXnDJFKeHsmpPhrMbnIyWVtvFfBxCVLAgmBkMN-HRyfSnX93ZyMfeiDoFzNIo9mkatZ5NksVfTm8YQPkv_WIP8Abm7BuQ</recordid><startdate>20240320</startdate><enddate>20240320</enddate><creator>Gao, Tianqi</creator><creator>Deng, Hong</creator><creator>Sheng, Jianhua</creator><creator>Wu, Bin</creator><creator>Liu, Zhening</creator><creator>Yang, Fude</creator><creator>Wang, Lina</creator><creator>Hu, Shaohua</creator><creator>Wang, Xijin</creator><creator>Li, Haiyun</creator><creator>Pu, Chengcheng</creator><creator>Yu, Xin</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20240320</creationdate><title>Improvement of social functioning in patients with first-episode schizophrenia using blonanserin treatment: a prospective, multi-centre, single-arm clinical trial</title><author>Gao, Tianqi ; Deng, Hong ; Sheng, Jianhua ; Wu, Bin ; Liu, Zhening ; Yang, Fude ; Wang, Lina ; Hu, Shaohua ; Wang, Xijin ; Li, Haiyun ; Pu, Chengcheng ; Yu, Xin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-16f979b16d6f74d8f529cac80ec1d3f4407bb266249980bd7b2a127e3e5cae103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>blonanserin</topic><topic>clinical trial</topic><topic>first-episode schizophrenia</topic><topic>Psychiatry</topic><topic>social functioning</topic><topic>symtomatic and neurocognitive improvement</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gao, Tianqi</creatorcontrib><creatorcontrib>Deng, Hong</creatorcontrib><creatorcontrib>Sheng, Jianhua</creatorcontrib><creatorcontrib>Wu, Bin</creatorcontrib><creatorcontrib>Liu, Zhening</creatorcontrib><creatorcontrib>Yang, Fude</creatorcontrib><creatorcontrib>Wang, Lina</creatorcontrib><creatorcontrib>Hu, Shaohua</creatorcontrib><creatorcontrib>Wang, Xijin</creatorcontrib><creatorcontrib>Li, Haiyun</creatorcontrib><creatorcontrib>Pu, Chengcheng</creatorcontrib><creatorcontrib>Yu, Xin</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Frontiers in psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gao, Tianqi</au><au>Deng, Hong</au><au>Sheng, Jianhua</au><au>Wu, Bin</au><au>Liu, Zhening</au><au>Yang, Fude</au><au>Wang, Lina</au><au>Hu, Shaohua</au><au>Wang, Xijin</au><au>Li, Haiyun</au><au>Pu, Chengcheng</au><au>Yu, Xin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improvement of social functioning in patients with first-episode schizophrenia using blonanserin treatment: a prospective, multi-centre, single-arm clinical trial</atitle><jtitle>Frontiers in psychiatry</jtitle><addtitle>Front Psychiatry</addtitle><date>2024-03-20</date><risdate>2024</risdate><volume>15</volume><spage>1345978</spage><epage>1345978</epage><pages>1345978-1345978</pages><issn>1664-0640</issn><eissn>1664-0640</eissn><abstract>This clinical trial primarily aimed to investigate the effects of blonanserin on social functioning in patients with first-episode schizophrenia. In this prospective, multi-centre, single-arm clinical trial study, blonanserin (flexible oral dose ranging from 8mg to 24mg per day) was given 26 weeks. Outcome measures included the Personal and Social Performance (PSP) scale for evaluating social functioning, the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB) for measuring neurocognitive performance, and the Positive and Negative Syndrome Scale (PANSS) for assessing symptom severity. The primary endpoint was social function improvement evaluated by PSP scale at the end of blonanserin treatment. And the secondary endpoint was to validate the efficacy and neurocognitive effects of blonanserin. Adverse drug reactions (ADRs) were also recorded and analysed. A total of 96 patients with first-episode schizophrenia were recruited and proceeded to analysis. Fifty-one participants (53.1%) completed the PSP scale measurements at baseline and week 26. Following 26 weeks of blonanserin treatment, all outcome measurements demonstrated significant improvement during the follow-up period. Notably, PSP scores exhibited a continuous increase up to 68.1% ± 103.7% at the end of the treatment (46.6 ± 14.6 at baseline, 69.4 ± 17.4 at week 26, p&lt;0.001), indicating positive effects on social functioning that were already noticeable by week 8. Blonanserin treatment exhibited favourable effects on social functioning in individuals with first-episode schizophrenia. The results suggest that blonanserin was effective treatment options for patients with schizophrenia encountering functional impairments.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>38571994</pmid><doi>10.3389/fpsyt.2024.1345978</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-0640
ispartof Frontiers in psychiatry, 2024-03, Vol.15, p.1345978-1345978
issn 1664-0640
1664-0640
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_af6c298ac1d64696bcd29c2b80ad2944
source PubMed (Medline)
subjects blonanserin
clinical trial
first-episode schizophrenia
Psychiatry
social functioning
symtomatic and neurocognitive improvement
title Improvement of social functioning in patients with first-episode schizophrenia using blonanserin treatment: a prospective, multi-centre, single-arm clinical trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T05%3A19%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improvement%20of%20social%20functioning%20in%20patients%20with%20first-episode%20schizophrenia%20using%20blonanserin%20treatment:%20a%20prospective,%20multi-centre,%20single-arm%20clinical%20trial&rft.jtitle=Frontiers%20in%20psychiatry&rft.au=Gao,%20Tianqi&rft.date=2024-03-20&rft.volume=15&rft.spage=1345978&rft.epage=1345978&rft.pages=1345978-1345978&rft.issn=1664-0640&rft.eissn=1664-0640&rft_id=info:doi/10.3389/fpsyt.2024.1345978&rft_dat=%3Cproquest_doaj_%3E3033008070%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c420t-16f979b16d6f74d8f529cac80ec1d3f4407bb266249980bd7b2a127e3e5cae103%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3033008070&rft_id=info:pmid/38571994&rfr_iscdi=true